MRUS – Merus N.V
Float Short %
2.59
Margin Of Safety %
Put/Call OI Ratio
EPS Next Q Diff
-0.09
EPS Last/This Y
-2.37
EPS This/Next Y
0.59
Price
90
Target Price
97
Analyst Recom
2.75
Performance Q
-3.92
Relative Volume
Beta
1.19
Ticker: MRUS
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-12-09 | MRUS | 96.37 | 1.63 | 0.30 | 57865 |
| 2025-12-10 | MRUS | 96.77 | 1.67 | 0.63 | 57590 |
| 2025-12-11 | MRUS | 96.65 | 1.67 | 1.86 | 58124 |
| 2025-12-12 | MRUS | 96.91 | 1.73 | 31.79 | 58848 |
| 2025-12-15 | MRUS | 96.83 | 1.86 | 2.24 | 60538 |
| 2025-12-16 | MRUS | 96.91 | 1.78 | 1.66 | 59855 |
| 2025-12-17 | MRUS | 96.91 | 1.82 | 34.56 | 60184 |
| 2025-12-18 | MRUS | 96.83 | 1.84 | 0.75 | 60676 |
| 2025-12-19 | MRUS | 96.93 | 1.81 | 1.93 | 61399 |
| 2025-12-22 | MRUS | 96.96 | 1.75 | 10.06 | 42279 |
| 2025-12-23 | MRUS | 96.93 | 1.78 | 0.10 | 42260 |
| 2025-12-26 | MRUS | 96.93 | 1.67 | 0.02 | 44281 |
| 2025-12-29 | MRUS | 89.73 | 2.09 | 0.25 | 41736 |
| 2025-12-30 | MRUS | 90 | 2.09 | 0.37 | 41736 |
| 2025-12-31 | MRUS | 90 | 2.09 | 0.37 | 41736 |
| 2026-01-02 | MRUS | 90 | 2.09 | 0.37 | 41736 |
| 2026-01-05 | MRUS | 90 | 2.09 | 0.37 | 41736 |
| 2026-01-06 | MRUS | 90 | N/A | N/A | 0 |
| 2026-01-07 | MRUS | 90 | N/A | N/A | 0 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-12-09 | MRUS | 96.36 | -116.3 | 1.5 | -5.68 |
| 2025-12-10 | MRUS | 96.79 | -116.3 | 0.1 | -5.68 |
| 2025-12-11 | MRUS | 96.66 | -116.3 | 2.4 | -5.68 |
| 2025-12-12 | MRUS | 96.91 | -116.3 | 0.7 | -5.68 |
| 2025-12-15 | MRUS | 96.82 | -116.3 | 2.4 | -5.68 |
| 2025-12-16 | MRUS | 96.82 | -116.3 | 2.0 | -5.68 |
| 2025-12-17 | MRUS | 96.90 | -116.3 | 2.0 | -5.68 |
| 2025-12-18 | MRUS | 96.84 | -116.3 | 2.2 | -5.68 |
| 2025-12-19 | MRUS | 96.93 | -116.3 | 1.5 | -5.68 |
| 2025-12-22 | MRUS | 96.95 | -116.3 | 1.8 | -5.68 |
| 2025-12-23 | MRUS | 96.92 | -116.3 | 2.1 | -5.68 |
| 2025-12-26 | MRUS | 96.93 | -116.3 | 1.8 | -5.68 |
| 2025-12-29 | MRUS | 90.00 | -116.3 | 30.7 | -5.68 |
| 2025-12-30 | MRUS | 90.00 | -116.3 | 1.9 | -5.68 |
| 2025-12-31 | MRUS | 90.00 | -116.3 | 1.9 | -5.68 |
| 2026-01-02 | MRUS | 90.00 | -108.6 | 1.9 | -5.72 |
| 2026-01-05 | MRUS | 90.00 | -102.7 | 1.9 | -5.72 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-12-09 | MRUS | -1.54 | -7.49 | 2.18 |
| 2025-12-10 | MRUS | -1.54 | -7.49 | 2.24 |
| 2025-12-11 | MRUS | -1.57 | -7.49 | 2.24 |
| 2025-12-12 | MRUS | -1.57 | -7.49 | 2.24 |
| 2025-12-15 | MRUS | -1.58 | -7.38 | 2.24 |
| 2025-12-16 | MRUS | -1.58 | -7.38 | 2.24 |
| 2025-12-17 | MRUS | -1.58 | -7.38 | 2.24 |
| 2025-12-18 | MRUS | -1.58 | -7.38 | 2.24 |
| 2025-12-19 | MRUS | 3.20 | -7.38 | 2.24 |
| 2025-12-22 | MRUS | 3.30 | -7.37 | 4.98 |
| 2025-12-23 | MRUS | 1.04 | -7.37 | 4.98 |
| 2025-12-26 | MRUS | 1.12 | -7.37 | 2.59 |
| 2025-12-29 | MRUS | 1.12 | -7.38 | 2.59 |
| 2025-12-30 | MRUS | 3.04 | -7.38 | 2.59 |
| 2025-12-31 | MRUS | 5.63 | -7.38 | 2.59 |
| 2026-01-02 | MRUS | 5.63 | -7.38 | 2.59 |
| 2026-01-05 | MRUS | 5.63 | 0 | 2.59 |
| 2026-01-06 | MRUS | 5.63 | 0 | 2.59 |
| 2026-01-07 | MRUS | 5.63 | 0 | 2.59 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-1.23
Avg. EPS Est. Current Quarter
-1.02
Avg. EPS Est. Next Quarter
-1.32
Insider Transactions
5.63
Institutional Transactions
Beta
1.19
Average Sales Estimate Current Quarter
9
Average Sales Estimate Next Quarter
11
Fair Value
Quality Score
19
Growth Score
36
Sentiment Score
73
Actual DrawDown %
7.3
Max Drawdown 5-Year %
-60.4
Target Price
97
P/E
Forward P/E
PEG
P/S
120.59
P/B
8.81
P/Free Cash Flow
EPS
-5.33
Average EPS Est. Cur. Y
-5.72
EPS Next Y. (Est.)
-5.14
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-673.31
Relative Volume
Return on Equity vs Sector %
-76.5
Return on Equity vs Industry %
-61.1
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.04
EBIT Estimation
1.9
Merus N.V.Sector: Healthcare
Industry: Biotechnology
Employees: 260
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cell lymphoma; and INCA33890 for advanced solid tumors. In addition, it has collaboration agreement with Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., and Betta Pharmaceuticals Co. Ltd. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands. As of December 11, 2025, Merus N.V. operates as a subsidiary of Genmab A/S.
stock quote shares MRUS – Merus N.V Stock Price stock today
news today MRUS – Merus N.V stock forecast ,stock prediction 2023 2024 2025
marketwatch MRUS – Merus N.V yahoo finance google finance
stock history MRUS – Merus N.V invest stock market
stock prices MRUS premarket after hours
ticker MRUS fair value insiders trading